|
Published by: BioSeeker Group AB
Published: Jul. 19, 2007 - 197 Pages
Table of Contents
- 1 Executive Summary
- 2 About Cancer Highlights
- 3 Methodologies
- 4 Table of Contents
- 4.1 List of Boxes
- 4.2 List of Tables
- 5 Etiology and Pathophysiology
- 6 Current Treatment Strategies
- 6.1 An Overview
- 6.2 Cytotoxic Drugs
- 6.2.1 Dacarbazine
- 6.2.2 Cisplatin
- 6.2.3 Carboplatin
- 6.2.4 Carmustine
- 6.2.5 Melphalan
- 6.2.6 Paclitaxel
- 6.2.7 Tamoxifen
- 6.2.8 Temozolomide
- 6.2.9 Vinblastine/Vinorelbine
- 6.3 Biological treatments
- 6.3.1 Intron A
- 6.3.2 Virulizin
- 6.3.3 Melacine
- 6.3.4 Alfanative (Multiferon)
- 6.3.5 Proleukin or (Macrolin)
- 6.3.6 Enhanzyn
- 6.3.7 M-VAX
- 6.4 Other
- 6.4.1 Ceplene Maxamine
- 7 Key Therapy Strategies
- 7.1 Immunotherapy
- 7.2 Anti-angiogenesis
- 7.3 Apoptotic Induction
- 7.4 Gene Therapy
- 8 Current Melanoma Drug Development: Late Stage Pipeline
- 8.1 Immunotherapy
- 8.1.1 Oncophage
- 8.1.2 Canvaxin
- 8.1.3 GMK
- 8.1.4 MDX-010
- 8.1.5 OncoVax
- 8.1.6 ALLOVECTIN-7
- 8.1.7 Peginterferon alfa-2b
- 8.2 Anti-angiogenesis
- 8.2.1 Lenalidomide
- 8.3 Apoptotic Inducers
- 8.3.1 Genasense
- 8.4 Inhibiting Cell Growth
- 8.4.1 Temozolomide
- 9 Current Melanoma Drug Development: Early Stage Pipeline
- 9.1 Immunotherapy
- 9.1.1 INGN 241
- 9.1.2 QS-21
- 9.1.3 Talabostat
- 9.1.4 SB 249553
- 9.1.5 GVAX
- 9.1.6 GV 1001
- 9.1.7 Dexosome
- 9.1.8 Uvidem
- 9.1.9 NY-ESO-1 ISCOMS
- 9.1.10 NOVOVAC-M1
- 9.1.11 Oxxon Vaccine
- 9.1.12 Therion’s Melanoma Vaccine
- 9.1.13 ImmunoVex trimelan
- 9.1.14 OncoVEXGM-CSF
- 9.1.15 Zadaxin
- 9.1.16 Alvac-Mage1/Mage3
- 9.1.17 Iboctadekin
- 9.1.18 ProMune
- 9.1.19 BAY 504798
- 9.1.20 EMD 273063
- 9.2 Antiangiogenesis
- 9.2.1 Sorafenib
- 9.2.2 Vitaxin
- 9.2.3 Avastin
- 9.2.4 PI
- 9.3 Apoptotic Inducers
- 9.3.1 Didemnin B
- 9.3.2 KOS 953
- 9.4 Small Molecules Inhibiting Cell Growth
- 9.4.1 Pivanex
- 9.4.2 Karenitecin
- 9.4.3 Lomeguatrib
- 9.4.4 PD 0325901
- 9.4.5 SB 715992
- 9.4.6 INO 1001
- 9.4.7 CP 4055
- 9.5 Other Biological Drugs
- 9.5.1 AP 12009
- 9.5.2 Ecromeximab
- 9.5.3 ILX 651
- 9.5.4 Kahalalide F
- 9.5.5 ABX MA1
- 9.5.6 MJV 101
- 9.5.7 A Russian Melanoma Vaccine
- 9.5.8 Elea Vaccine
- 9.5.9 F 50040
- 10 Appendix I: Treatment Guide Lines Melanoma
- 11 Disclaimer
- 12 Drug Index
- 13 Company Index
- 4.1 List of Boxes
- Box 1: Quick Facts - Enhanzyn
- Box 2: Quick Facts - M-VAX
- Box 3: M-VAX - Business & Market Bakground
- Box 4: Mechanisms which Tumor Cells use to Evade an Immune Reaction
- Box 5: Introgen’s INGN 241 Shows Vaccine Properties
- Box 6: Quick Facts - Oncophage
- Box 7: Oncophage - Designation and Status
- Box 8: Quick Facts - Canvaxin
- Box 9: Canvaxin - Designation and Status
- Box 10: CancerVax Milestone payment
- Box 11: Quick Facts - GM2-KLH Vaccine
- Box 12: Progenics Reaquires Rights to Vaccine
- Box 13: Completed Melanoma Phase III trial
- Box 14: Quick Facts - MDX-010
- Box 15: Quick Facts -OncoVax
- Box 16: Quick Facts - ALLOVECTIN-7
- Box 17: Quick Facts - Peginterferon alfa-2b
- Box 18: Introgen’s INGN 241 Shows Anti-angiogenesis Properties
- Box 19: Quick Facts - Lenalidomide
- Box 20: Quick Facts - Oblimersen
- Box 21: Quick Facts - Temozomide
- Box 22: Molecular Pathways Underlying the Activity of Temozolomide’s Anti-Cancer Therapy
- Box 23: Regulatory Progress
- Box 24: Quick Facts - INGN 241
- Box 25: Molecular Pathways Underlying Activity of Introgen's INGN 241 Anti-Cancer Therapy
- Box 26: Quick Facts - QS-21
- Box 27: Quick Facts - Talabostat
- Box 28: Quick Facts - SB 249553
- Box 29: Quick Facts - GVAX
- Box 30: Agreement Japan Tobacco and Cell Genesys
- Box 31: Predicted launch of GVAX
- Box 32: Quick Facts - GV 1001
- Box 33: Quick Facts - Dexosome
- Box 34: Important Milestones and License Fees
- Box 35: Quick Facts - Uvidem
- Box 36: Agreements Between Sanofi-Aventis and IDM
- Box 37: Quick Facts - NY-ESO-1 ISCOMS
- Box 38: NY-ESO-1 and ISCOMATRIX
- Box 39: Quick Facts - NovoVac-M1
- Box 40: Quick Facts - Oxxon vaccine
- Box 41: Quick Facts - Therion’s Melanoma Vaccine
- Box 42: Quick Facts - ImmunoVEX trimelan
- Box 43: Quick Facts - OncoVEX GM-CSF
- Box 44: Quick Facts - ZADAXIN
- Box 45: Developmental History Thymosin alpha1
- Box 46: Quick Facts - Alvac-Mage1/Mage3
- Box 47: Quick Facts - iboctadekin
- Box 48: Quick Facts - PF-3512676
- Box 49: Quick Facts - BAY-504798
- Box 50: Quick Facts - EMD-273063
- Box 51: Quick Facts - Sorefenib
- Box 52: Quick Facts - Vitaxin
- Box 53: Quick Facts . Bevacizumab
- Box 54: Quick Facts - PI88
- Box 55: Quick Facts - Didemnin B
- Box 56: Quick Facts - KOS 953
- Box 57: Quick Facts - Pivanex
- Box 58: Quick Facts - Karenitecin
- Box 59: Company Statement
- Box 60: Quick Facts - Lomeguatrib
- Box 61: Quick Facts - PD 0325901
- Box 62: Quick Facts - SB 715992
- Box 63: Quick Facts - INO 1001
- Box 64: Quick Facts - CP 4055
- Box 65: Quick Facts - AP 12009
- Box 66: Quick Facts - Ecromeximab
- Box 67: Quick Facts - ILX 651
- Box 68: Quick Facts - Kahalalide F
- Box 69: Quick Facts - ABX MA1
- Box 70: Quick Facts - MJV 101
- Box 71: Quick Facts - Russian Melanoma Vaccine
- Box 72: Quick Facts - N-Acetyl-GM3 ganglioside
- Box 73: Quick Facts - F 5004
- Box 74: KpOmpA Technology
- 4.2 List of Tables
- Table 1: Critical Risk Factors for Development of Melanoma
- Table 2: Definition and Description of Stages of Melanoma
- Table 3: Prognosis of the 4 Stages of Malignant Melanoma
- Table 4: Current Cytotoxic Drugs for the Treatment of Melanoma
- Table 5: Progress Profile Dacarbazine
- Table 6: Progress Profile Cisplatin
- Table 7: Progress Profile Carboplatin
- Table 8: Progress Profile Carmustine
- Table 9: Progress Profile Melphalan
- Table 10: Progress Profile Paclitaxel
- Table 11: Progress Profile Tamoxifen
- Table 12: Progress Profile Temozolomide
- Table 13: Progress Profile Vinblastine/Vinorelbine
- Table 14: Progress Profile Interferon alfa-2b
- Table 15: Development Milestones- Virulizin
- Table 16: Development Milestones - Melacine
- Table 17: Development Milestones - Alfanative
- Table 18: Development Milestones - Proleukin
- Table 19: Deployed Strategies for Blocking Angiogenesis
- Table 20: Phase III Randomized Studies of Melanoma Vaccines.
- Table 21: Tumor antigen based vaccines
- Table 22: In vivo Gene Therapy
- Table 23: Cell Therapy Based Platform in Pipeline as Potential Treatment of Melanoma
- Table 24: Ex vivo gene therapy loading of antigen presenting cells
- Table 25: Overview of Immunostimulants in Development based on Type
- Table 26: Overview of Immuno-Biologicals
- Table 27: Overview of Gene Therapy Drugs for Immunostimulation
- Table 28: MDX-010’s Collaborative History and Landscape
- Table 29: Anti-angiogenisis Drugs under Development
- Table 30: Overview Apoptopic Inducer Drugs
- Table 31: Overview of Small Molecule Drugs
- Table 32:Selected Regulatory Progress of Sorafenib
- Table 33: Selected Regulatory Progress of Didemin B
- Table 34: Overview of Various Biological Drugs in Development for Melanoma
AbstractThe risk of malignant melanoma has more than doubled in the past decade. The incidence of melanoma is rising faster than that of any other cancer. In the current alternatives for the treatment of malignant melanoma several combinatory treatments are used. Melanoma drug development has and will continue to have a strong focus on target therapy such as cancer vaccines, monoclonal antibodies, biological drugs, antiangiogenesis, apoptotic inducers and gene therapy. In recent years, immunologic strategies including tumor vaccine and adjuvant therapy with interferon-alfa have been attempted to improve survival of patients with more advanced malignant melanoma. Another emerging strategy in anticancer therapy is the targeting of chemotherapy resistance by overcoming the antiapoptosis mechanisms of cancer cells and antiangiogenesis.
This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field. No less than 68 approved drugs and drug candidates have been studied. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. New interesting phase III studies have been initiated. By gathering information around most drugs under development for melanoma and specially the late stage pipeline it has been clear that four major therapeutic strategies generated the most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments.
This report covers the latest on:
- Analysis of current treatment and key therapeutic strategies
- Progress analysis of on more than 50 pipeline products, including emerging and hot pre-clinical data, discontinued projects, clinical trial information, commercial potential and limiting factors.
- Enables competitive landscape analysis
- Achievements from the most important companies in melanoma R&D
Example of drugs included in this analysis:
- ABX MA1, Alfanative , ALLOVECTIN-7, AP 12009, Avastin, BAY 504798, Canvaxin, Carboplatin, Carmustine, Ceplene Maxamine, Cisplatin, CP 4055, Dacarbazine, Dexosome, Didemnin B, Ecromeximab, Elea Vaccine, EMD 273063, Enhanzyn, F 50040, Genasense, GMK, GV 1001, GVAX, Iboctadekin, ILX 651, INGN 241, INO 1001, Intron A, Kahalalide F, Karenitecin, KOS 953, Lenalidomide, Lomeguatrib, MDX-010, Melacine, Melphalan, MJV 101, M-VAX, NOVOVAC-M1, NY-ESO-1 ISCOMS, Oncophage, OncoVax, OncoVEXGM-CSF, Paclitaxel, PD 0325901, Peginterferon alfa-2b, Pivanex, Proleukin , ProMune, QS-21, SB 249553, SB 715992, Sorafenib, Talabostat, Tamoxifen, Temozolomide, Temozolomide, Uvidem, Vinblastine/Vinorelbine, Virulizin, Vitaxin, Zadaxin
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
